Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPAST | Q9UBP0 | 2/20 | 0.77 |
| ▸ | PAK4 | O96013 | 2/20 | 0.46 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.46 |
| ▸ | IGF1R | P08069 | 5/20 | 0.41 |
| ▸ | HTR2A | P28223 | 5/20 | 0.40 |
| ▸ | AURKA | O14965 | 2/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22035048 | 0.87 | SPAST (1.00) | SPASTPAK4PAK1IGF1RHTR2A | |
| SCHEMBL22035049 | 0.87 | SPAST (1.00) | SPASTPAK4PAK1IGF1RHTR2A | |
| SCHEMBL22072044 | 0.86 | SPAST (0.56) | SPASTPAK4PAK1HTR2AAURKA | |
| SCHEMBL22072040 | 0.79 | SPAST (0.59) | SPASTPAK4PAK1HTR2AAURKA | |
| SCHEMBL22072740 | 0.75 | SPAST (0.76) | SPASTPAK4PAK1IGF1RAURKA | |
| SCHEMBL22072741 | 0.74 | SPAST (0.76) | SPASTPAK4PAK1IGF1R | |
| SCHEMBL22072528 | 0.74 | SPAST (0.75) | SPASTPAK4PAK1IGF1R | |
| SCHEMBL22072083 | 0.73 | SPAST (0.61) | SPASTPAK4PAK1IGF1RAURKA | |
| SCHEMBL22072085 | 0.73 | PAK4 (0.66) | PAK4PAK1 | |
| SCHEMBL22034758 | 0.73 | SPAST (0.74) | SPASTPAK4PAK1IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020118183-A1 | 2,4-DIAMINOPYRIMIDINE BICYCLES FOR TREATING CANCER | KAPOOR TARUN M (US) | 2020-06-11 | — | — | WO | disclosed |